Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-12-04
Disclosure Type: Execution of Single Sales/Supply Contract (Correction)
💡 3-Second Summary
Samsung Biologics has extended the confidentiality period regarding the identity of its client for a KRW 144.6B medicine contract manufacturing (CMO) agreement, signed in 2018, from the end of 2025 to December 31, 2028, at the client’s request. The contract end date has been adjusted to December 31, 2028, and a clause has been added indicating that the minimum guaranteed contract amount may increase if the client’s demand rises.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Reason for Amendment: Extension of disclosure deferment period (maintenance of business confidentiality) and specification of contract terms at the client’s request.
- Contract Amount: KRW 144,610,010,460 (Approximately KRW 144.6B)
- This figure represents the fixed minimum guaranteed contract amount of USD 127,555,800 applied with the initial standard trading exchange rate of 1,133.70 KRW/USD as of August 14, 2018.
- Ratio to Sales: 31.12% (Compared to the recent annual sales of KRW 464.6B from the 2017 consolidated financial statements).
- Counterparty: A pharmaceutical company based in Asia (The identity remains confidential due to business secrecy until December 31, 2028, subject to change).
- Contract Period: August 14, 2018 (Start Date) to December 31, 2028 (End Date).
- Key Conditions: No contract deposit or down payment. The contract end date and total amount may fluctuate based on mutual agreement. If the client’s demand increases, the fixed minimum guaranteed contract amount may be raised upon further consultation.
📈 2. [Expert View: What This Disclosure Means for Investors]
- Adjustment of Contract Terms and Timelines: This correction disclosure formalizes that the contract end date and disclosure deferment period have been adjusted to December 31, 2028, based on mutual agreement and the client’s request. Since this filing strictly reports administrative changes to contract terms and disclosure schedules, investors should focus on these factual modifications rather than expanding them into assumptions about actual contract execution rates or operational performance.
- Implications of Extending Confidentiality: Extending the business confidentiality period to 2028 regarding the counterparty’s identity is an administrative step taken to meet the client’s security needs. While this indicates that the procedural terms have been extended without cancellation or reduction, the actual operational progress and potential future adjustments of the contract remain subject to ongoing tracking through subsequent regulatory disclosures.
- Potential Capacity for Contract Amount Modification: The clause stating that the “minimum guaranteed contract amount could increase upon consultation if client demand grows” introduces a potential opportunity for future adjustment in the total value. However, because the disclosure does not explicitly state the specific causes for performance changes or provide guaranteed figures, investors are encouraged to treat this as a potential impact rather than an absolute projection of guaranteed growth.
📝 Editor’s Comment (by K-STOCK Editor)
This regulatory correction from Samsung Biologics provides objective documentation that the confidentiality timeline and contract end date for a CMO agreement initially reported in 2018 have been rescheduled to the end of 2028. In the global biopharmaceutical market, adjusting disclosure deferment periods to protect a client’s corporate information is a standard administrative procedure. From an investor’s standpoint, while the potential clause for contract value scaling should be recognized, it is critical to view this filing purely as an administrative adjustment of conditions rather than a definitive guarantee of contract fulfillment or backlog stability. Investors should utilize this update primarily as an objective indicator of modified contract terms.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official submission data from the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!